Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured By Positron Emission Tomography in Clinically Normal Older Adults.

Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S, Hanseeuw BJ, Jacobs HIL, Papp KV, Amariglio RE, Properzi MJ, Schultz AP, Kirn D, Scott MR, Hedden T, Farrell M, Price J, Chhatwal J, Rentz DM, Villemagne VL, Johnson KA, Sperling RA.

JAMA Neurol. 2019 Feb 4. doi: 10.1001/jamaneurol.2018.4693. [Epub ahead of print]

PMID:
30715078
2.

Vascular Risk and β-Amyloid Are Synergistically Associated with Cortical Tau.

Rabin JS, Yang HS, Schultz AP, Hanseeuw BJ, Hedden T, Viswanathan A, Gatchel JR, Marshall GA, Kilpatrick E, Klein H, Rao V, Buckley RF, Yau WW, Kirn DR, Rentz DM, Johnson KA, Sperling RA, Chhatwal JP.

Ann Neurol. 2019 Feb;85(2):272-279. doi: 10.1002/ana.25399. Epub 2019 Jan 7.

PMID:
30565287
3.

The impact of amyloid-beta and tau on prospective cognitive decline in older individuals.

Sperling RA, Mormino EC, Schultz AP, Betensky RA, Papp KV, Amariglio RE, Hanseeuw BJ, Buckley R, Chhatwal J, Hedden T, Marshall GA, Quiroz YT, Donovan NJ, Jackson J, Gatchel JR, Rabin JS, Jacobs H, Yang HS, Properzi M, Kirn DR, Rentz DM, Johnson KA.

Ann Neurol. 2019 Feb;85(2):181-193. doi: 10.1002/ana.25395. Epub 2019 Jan 21.

PMID:
30549303
4.

Effect of exercise and nutritional supplementation on health-related quality of life and mood in older adults: the VIVE2 randomized controlled trial.

von Berens Å, Fielding RA, Gustafsson T, Kirn D, Laussen J, Nydahl M, Reid K, Travison TG, Zhu H, Cederholm T, Koochek A.

BMC Geriatr. 2018 Nov 21;18(1):286. doi: 10.1186/s12877-018-0976-z.

5.

Translating the Lifestyle Interventions and Independence for Elders Clinical Trial to Older Adults in a Real-World Community-Based Setting.

Reid KF, Laussen J, Bhatia K, Englund DA, Kirn DR, Price LL, Manini TM, Liu CK, Kowaleski C, Fielding RA.

J Gerontol A Biol Sci Med Sci. 2019 May 16;74(6):924-928. doi: 10.1093/gerona/gly152.

PMID:
30010808
6.

Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts.

Buckley RF, Mormino EC, Amariglio RE, Properzi MJ, Rabin JS, Lim YY, Papp KV, Jacobs HIL, Burnham S, Hanseeuw BJ, Doré V, Dobson A, Masters CL, Waller M, Rowe CC, Maruff P, Donohue MC, Rentz DM, Kirn D, Hedden T, Chhatwal J, Schultz AP, Johnson KA, Villemagne VL, Sperling RA; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging, Biomarker and Lifestyle study of ageing; Harvard Aging Brain Study.

Alzheimers Dement. 2018 Sep;14(9):1193-1203. doi: 10.1016/j.jalz.2018.04.010. Epub 2018 May 24.

PMID:
29803541
7.

Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study.

Rabin JS, Schultz AP, Hedden T, Viswanathan A, Marshall GA, Kilpatrick E, Klein H, Buckley RF, Yang HS, Properzi M, Rao V, Kirn DR, Papp KV, Rentz DM, Johnson KA, Sperling RA, Chhatwal JP.

JAMA Neurol. 2018 Sep 1;75(9):1124-1131. doi: 10.1001/jamaneurol.2018.1123.

8.

"Feeling More Self-Confident, Cheerful and Safe". Experiences from a Health-Promoting Intervention in Community Dwelling Older Adults - A Qualitative Study.

von Berens Å, Koochek A, Nydahl M, Fielding RA, Gustafsson T, Kirn DR, Cederholm T, Södergren M.

J Nutr Health Aging. 2018;22(4):541-548. doi: 10.1007/s12603-017-0981-5.

PMID:
29582895
9.

Physical Performance and Serum 25(OH)vitamin D Status in Community Dwelling Old Mobility Limited Adults: A Cross-Sectional Study.

von Berens Å, Cederholm T, Fielding RA, Gustafsson T, Kirn D, Laussen J, Nydahl M, Travison TG, Reid K, Koochek A.

J Nutr Health Aging. 2018;22(1):1-7. doi: 10.1007/s12603-016-0849-0.

PMID:
29300415
10.

Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms.

Kim M, Nitschké M, Sennino B, Murer P, Schriver BJ, Bell A, Subramanian A, McDonald CE, Wang J, Cha H, Bourgeois-Daigneault MC, Kirn DH, Bell JC, De Silva N, Breitbach CJ, McDonald DM.

Cancer Res. 2018 Feb 15;78(4):922-937. doi: 10.1158/0008-5472.CAN-15-3308. Epub 2017 Dec 19.

11.

Effect of Structured Physical Activity and Nutritional Supplementation on Physical Function in Mobility-Limited Older Adults: Results from the VIVE2 Randomized Trial.

Fielding RA, Travison TG, Kirn DR, Koochek A, Reid KF, von Berens Å, Zhu H, Folta SC, Sacheck JM, Nelson ME, Liu CK, Åberg AC, Nydahl M, Lilja M, Gustafsson T, Cederholm T.

J Nutr Health Aging. 2017;21(9):936-942. doi: 10.1007/s12603-017-0936-x.

PMID:
29083433
12.

Nutritional Supplementation With Physical Activity Improves Muscle Composition in Mobility-Limited Older Adults, The VIVE2 Study: A Randomized, Double-Blind, Placebo-Controlled Trial.

Englund DA, Kirn DR, Koochek A, Zhu H, Travison TG, Reid KF, von Berens Å, Melin M, Cederholm T, Gustafsson T, Fielding RA.

J Gerontol A Biol Sci Med Sci. 2017 Dec 12;73(1):95-101. doi: 10.1093/gerona/glx141.

13.

Efficacy of an Exercise and Nutritional Supplement Program on Physical Performance and Nutritional Status in Older Adults With Mobility Limitations Residing at Senior Living Facilities.

Corcoran MP, Nelson ME, Sacheck JM, Reid KF, Kirn D, Fielding RA, Chui KKH, Folta SC.

J Aging Phys Act. 2017 Jul;25(3):453-463. doi: 10.1123/japa.2016-0173. Epub 2017 Jun 28.

PMID:
28095099
14.

Accelerometer Assessment of Physical Activity and Its Association with Physical Function in Older Adults Residing at Assisted Care Facilities.

Corcoran MP, Chui KK, White DK, Reid KF, Kirn D, Nelson ME, Sacheck JM, Folta SC, Fielding RA.

J Nutr Health Aging. 2016;20(7):752-8. doi: 10.1007/s12603-015-0640-7.

PMID:
27499309
15.

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.

Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau IW, Weisel K, Hillengass J, Raab MS, Hose D, Goldschmidt H, Jauch A.

Haematologica. 2016 Mar;101(3):e116-9. doi: 10.3324/haematol.2015.136929. Epub 2015 Nov 26. No abstract available.

16.

What is a Clinically Meaningful Improvement in Leg-Extensor Power for Mobility-limited Older Adults?

Kirn DR, Reid KF, Hau C, Phillips EM, Fielding RA.

J Gerontol A Biol Sci Med Sci. 2016 May;71(5):632-6. doi: 10.1093/gerona/glv207. Epub 2015 Nov 18.

17.

VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.

Arulanandam R, Batenchuk C, Angarita FA, Ottolino-Perry K, Cousineau S, Mottashed A, Burgess E, Falls TJ, De Silva N, Tsang J, Howe GA, Bourgeois-Daigneault MC, Conrad DP, Daneshmand M, Breitbach CJ, Kirn DH, Raptis L, Sad S, Atkins H, Huh MS, Diallo JS, Lichty BD, Ilkow CS, Le Boeuf F, Addison CL, McCart JA, Bell JC.

Cancer Cell. 2015 Aug 10;28(2):210-24. doi: 10.1016/j.ccell.2015.06.009. Epub 2015 Jul 23.

18.

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.

Park SH, Breitbach CJ, Lee J, Park JO, Lim HY, Kang WK, Moon A, Mun JH, Sommermann EM, Maruri Avidal L, Patt R, Pelusio A, Burke J, Hwang TH, Kirn D, Park YS.

Mol Ther. 2015 Sep;23(9):1532-40. doi: 10.1038/mt.2015.109. Epub 2015 Jun 15.

19.

A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.

Breitbach CJ, Moon A, Burke J, Hwang TH, Kirn DH.

Methods Mol Biol. 2015;1317:343-57. doi: 10.1007/978-1-4939-2727-2_19.

PMID:
26072416
20.

The Vitality, Independence, and Vigor in the Elderly 2 Study (VIVE2): Design and methods.

Kirn DR, Koochek A, Reid KF, von Berens Å, Travison TG, Folta S, Sacheck J, Nelson M, Liu C, Phillips E, Åberg AC, Nydahl M, Gustafsson T, Cederholm T, Fielding RA.

Contemp Clin Trials. 2015 Jul;43:164-71. doi: 10.1016/j.cct.2015.06.001. Epub 2015 Jun 2.

PMID:
26044464
21.

Recruitment of Mobility Limited Older Adults Into a Facility-Led Exercise-Nutrition Study: The Effect of Social Involvement.

Corcoran MP, Nelson ME, Sacheck JM, Reid KF, Kirn D, Fielding RA, Folta SC.

Gerontologist. 2016 Aug;56(4):669-76. doi: 10.1093/geront/gnv018. Epub 2015 Mar 20.

PMID:
26035904
22.

Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.

Breitbach CJ, Parato K, Burke J, Hwang TH, Bell JC, Kirn DH.

Curr Opin Virol. 2015 Aug;13:49-54. doi: 10.1016/j.coviro.2015.03.016. Epub 2015 Apr 17. Review.

PMID:
25900822
23.

Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.

Evgin L, Acuna SA, Tanese de Souza C, Marguerie M, Lemay CG, Ilkow CS, Findlay CS, Falls T, Parato KA, Hanwell D, Goldstein A, Lopez R, Lafrance S, Breitbach CJ, Kirn D, Atkins H, Auer RC, Thurman JM, Stahl GL, Lambris JD, Bell JC, McCart JA.

Mol Ther. 2015 Jun;23(6):1066-1076. doi: 10.1038/mt.2015.49. Epub 2015 Mar 25.

24.

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).

Breitbach CJ, Bell JC, Hwang TH, Kirn DH, Burke J.

Oncolytic Virother. 2015 Jan 28;4:25-31. doi: 10.2147/OV.S59640. eCollection 2015. Review.

25.

Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.

Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, Towbin AJ, Rooney CM, Pelusio A, Moon A, Hwang TH, Burke JM, Bell JC, Kirn DH, Breitbach CJ.

Mol Ther. 2015 Mar;23(3):602-8. doi: 10.1038/mt.2014.243. Epub 2014 Dec 22.

26.

First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.

Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P, Wieckowski E, O'Malley ME, Daneshmand M, Hu K, Bell JC, Hwang TH, Moon A, Breitbach CJ, Kirn DH, Bartlett DL.

Mol Ther. 2015 Jan;23(1):202-14. doi: 10.1038/mt.2014.194. Epub 2014 Oct 8.

27.

Serum Predictors of Percent Lean Mass in Young Adults.

Lustgarten MS, Price LL, Phillips EM, Kirn DR, Mills J, Fielding RA.

J Strength Cond Res. 2016 Aug;30(8):2194-201. doi: 10.1519/JSC.0b013e31829eef24.

PMID:
23774283
28.

Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.

Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, Lee JW, Kim SG, Kang DH, Bell JC, Park BH, Kirn DH, Hwang TH.

Sci Transl Med. 2013 May 15;5(185):185ra63. doi: 10.1126/scitranslmed.3005361.

29.

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.

Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH.

Nat Med. 2013 Mar;19(3):329-36. doi: 10.1038/nm.3089. Epub 2013 Feb 10.

30.

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, Heo J, Cho M, Chen H, Angarita FA, Addison C, McCart JA, Bell JC, Kirn DH.

Cancer Res. 2013 Feb 15;73(4):1265-75. doi: 10.1158/0008-5472.CAN-12-2687. Epub 2013 Feb 7.

31.

Identification of serum analytes and metabolites associated with aerobic capacity.

Lustgarten MS, Price LL, Logvinenko T, Hatzis C, Padukone N, Reo NV, Phillips EM, Kirn D, Mills J, Fielding RA.

Eur J Appl Physiol. 2013 May;113(5):1311-20. doi: 10.1007/s00421-012-2555-x. Epub 2012 Nov 27.

PMID:
23184236
32.

Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells.

Tai LH, de Souza CT, Bélanger S, Ly L, Alkayyal AA, Zhang J, Rintoul JL, Ananth AA, Lam T, Breitbach CJ, Falls TJ, Kirn DH, Bell JC, Makrigiannis AP, Auer RA.

Cancer Res. 2013 Jan 1;73(1):97-107. doi: 10.1158/0008-5472.CAN-12-1993. Epub 2012 Oct 22.

33.

Nanoscale shuffling in a template-assisted self-assembly of binary colloidal particles.

Ikezoe Y, Kim SJ, Kirn D, Lee SB, Hara M.

J Nanosci Nanotechnol. 2012 Mar;12(3):2934-8.

PMID:
22755145
34.

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC.

Mol Ther. 2012 Apr;20(4):749-58. doi: 10.1038/mt.2011.276. Epub 2011 Dec 20.

35.

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH.

Nature. 2011 Aug 31;477(7362):99-102. doi: 10.1038/nature10358.

PMID:
21886163
36.

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.

Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, Daneshmand M, De Silva N, Parato K, Diallo JS, Lee YS, Liu TC, Bell JC, Kirn DH.

Mol Ther. 2011 Oct;19(10):1913-22. doi: 10.1038/mt.2011.132. Epub 2011 Jul 19.

37.

Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.

Breitbach CJ, Thorne SH, Bell JC, Kirn DH.

Curr Pharm Biotechnol. 2012 Jul;13(9):1768-72. Review.

PMID:
21740365
38.

Redemption for the field of oncolytic virotherapy.

Kirn DH.

Mol Ther. 2011 Apr;19(4):627-8. doi: 10.1038/mt.2011.45. No abstract available.

39.

Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.

Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK, Lee YK, Oh SY, Woo HY, Parato K, Rintoul J, Falls T, Hickman T, Rhee BG, Bell JC, Kirn DH, Hwang TH.

Mol Ther. 2011 Jun;19(6):1170-9. doi: 10.1038/mt.2011.39. Epub 2011 Mar 22.

40.

Targeting tumor vasculature with an oncolytic virus.

Breitbach CJ, De Silva NS, Falls TJ, Aladl U, Evgin L, Paterson J, Sun YY, Roy DG, Rintoul JL, Daneshmand M, Parato K, Stanford MM, Lichty BD, Fenster A, Kirn D, Atkins H, Bell JC.

Mol Ther. 2011 May;19(5):886-94. doi: 10.1038/mt.2011.26. Epub 2011 Mar 1.

41.

Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14).

Bochtler T, Hegenbart U, Heiss C, Benner A, Moos M, Seckinger A, Pschowski-Zuck S, Kirn D, Neben K, Bartram CR, Ho AD, Goldschmidt H, Hose D, Jauch A, Schonland SO.

Blood. 2011 Apr 7;117(14):3809-15. doi: 10.1182/blood-2010-02-268987. Epub 2011 Feb 10.

42.

Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.

MacTavish H, Diallo JS, Huang B, Stanford M, Le Boeuf F, De Silva N, Cox J, Simmons JG, Guimond T, Falls T, McCart JA, Atkins H, Breitbach C, Kirn D, Thorne S, Bell JC.

PLoS One. 2010 Dec 30;5(12):e14462. doi: 10.1371/journal.pone.0014462.

43.

Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.

Lun X, Chan J, Zhou H, Sun B, Kelly JJ, Stechishin OO, Bell JC, Parato K, Hu K, Vaillant D, Wang J, Liu TC, Breitbach C, Kirn D, Senger DL, Forsyth PA.

Mol Ther. 2010 Nov;18(11):1927-36. doi: 10.1038/mt.2010.183. Epub 2010 Aug 31.

44.

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.

Huang B, Sikorski R, Kirn DH, Thorne SH.

Gene Ther. 2011 Feb;18(2):164-72. doi: 10.1038/gt.2010.121. Epub 2010 Aug 26.

PMID:
20739958
45.

Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.

Breitbach CJ, Reid T, Burke J, Bell JC, Kirn DH.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):85-9. doi: 10.1016/j.cytogfr.2010.02.001. Epub 2010 May 15. Review.

PMID:
20472490
46.

Recent advances in the development of oncolytic viruses as cancer therapeutics. Foreword.

Bell J, Kirn D.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):83-4. doi: 10.1016/j.cytogfr.2010.04.004. Epub 2010 May 4. No abstract available.

PMID:
20444639
47.

A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.

Diallo JS, Le Boeuf F, Lai F, Cox J, Vaha-Koskela M, Abdelbary H, MacTavish H, Waite K, Falls T, Wang J, Brown R, Blanchard JE, Brown ED, Kirn DH, Hiscott J, Atkins H, Lichty BD, Bell JC.

Mol Ther. 2010 Jun;18(6):1123-9. doi: 10.1038/mt.2010.67. Epub 2010 Apr 13.

48.

Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.

De Silva N, Atkins H, Kirn DH, Bell JC, Breitbach CJ.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):135-41. doi: 10.1016/j.cytogfr.2010.02.007. Epub 2010 Mar 24. Review.

PMID:
20338801
49.

Synergistic interaction between oncolytic viruses augments tumor killing.

Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, Kanji F, Auer R, Brown CW, Lichty BD, Parato K, Atkins H, Kirn D, Bell JC.

Mol Ther. 2010 May;18(5):888-95. doi: 10.1038/mt.2010.44. Epub 2010 Mar 16.

50.

Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.

Lee JH, Roh MS, Lee YK, Kim MK, Han JY, Park BH, Trown P, Kirn DH, Hwang TH.

Cancer Gene Ther. 2010 Feb;17(2):73-9. doi: 10.1038/cgt.2009.50. Epub 2009 Jul 24.

Supplemental Content

Support Center